UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000230
Receipt number R000000230
Scientific Title Effects of pioglitazone on coronary atherosclerotic plaques of patients with impaired glucose tolerance or type 2 diabetes mellitus:a randomized,open rabelled,prospective study.
Date of disclosure of the study information 2005/12/01
Last modified on 2010/09/14 04:35:38

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of pioglitazone on coronary atherosclerotic plaques of patients with impaired glucose tolerance or type 2 diabetes mellitus:a randomized,open rabelled,prospective study.

Acronym

Effects of pioglitazone on coronary atherosclerotic plaques:a randomized,open rabelled,prospective study of Pioglitazone Intervention on Coronary Atherosclerosis (PIGEON) using intravascular ultrasound.

Scientific Title

Effects of pioglitazone on coronary atherosclerotic plaques of patients with impaired glucose tolerance or type 2 diabetes mellitus:a randomized,open rabelled,prospective study.

Scientific Title:Acronym

Effects of pioglitazone on coronary atherosclerotic plaques:a randomized,open rabelled,prospective study of Pioglitazone Intervention on Coronary Atherosclerosis (PIGEON) using intravascular ultrasound.

Region

Japan


Condition

Condition

Impaired glucose tolerance or type 2 diabetes mellitus with coronary artery disease

Classification by specialty

Cardiology Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate reduction and stabilization of coronary atherosclerotic plaques by pioglitazone.

Basic objectives2

Pharmacodynamics

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase II,III


Assessment

Primary outcomes

Plaque volume,vessel volume,lumen volume and radiofrquency data assessed with intravascular ultrasound.
Plasma glucose,HbA1C,insulin,total cholesterol,triglyceride,LDL,HDL,MDA-LDL,8-isoprostane,MMP-9,MCP-1,PAI-1,TNF-a and hsCRP.
Major adverse cardiovascular event and harmful effect of pioglitazone

Key secondary outcomes

Plasma GOT,GPT,T-BIL,CPK,ALP,G-GTP and LDH


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Intervention group:Start to take pioglitazone 15mg per day after percutaneous coronary angioplasty and increase a dose to 30mg per day at 14days after angioplasty.And continue in 6 months.

Interventions/Control_2

Control group:Take no pioglitazone in 6 months after percutaneous coronary angioplasty.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

Patient who have impaired glucose tolerance or type 2 diabetes mellitus with undergoing percutaneous coronary angioplasty.

Key exclusion criteria

Heart failure,acute myocardial infarction,severe hepatic or renal dysfunction,to take insulin,already to take pioglitazone,episode of adverse effect by troglitazone,pregnancy and severe hypercholesterolemia.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Issei Komuro

Organization

Chiba University Graduate School of Medicine

Division name

Division of cardiovascular science and medicine

Zip code


Address

1-8-1 Inohana,Chu-o ku,Chiba city,Chiba,JAPAN

TEL

043-222-7171

Email



Public contact

Name of contact person

1st name
Middle name
Last name Takashi Nakayama

Organization

Chiba University Graduate School of Medicine

Division name

Division of cardiovascular science and medicine

Zip code


Address

1-8-1 Inohana,Chu-o ku,Chiba city,Chiba,JAPAN

TEL

043-222-7171

Homepage URL


Email



Sponsor or person

Institute

Chiba University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Kimitsu Central Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2005 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results

Published: Nakayama T, Komiyama N, Yokoyama M, Namikawa S, Kuroda N, Kobayashi Y, Komuro I. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol. 2010;138(2):157-165. Epub 2008 Sep 24.

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2003 Year 03 Month 01 Day

Date of IRB


Anticipated trial start date

2003 Year 03 Month 01 Day

Last follow-up date

2005 Year 12 Month 01 Day

Date of closure to data entry

2006 Year 08 Month 01 Day

Date trial data considered complete

2006 Year 08 Month 01 Day

Date analysis concluded

2006 Year 08 Month 01 Day


Other

Other related information



Management information

Registered date

2005 Year 09 Month 13 Day

Last modified on

2010 Year 09 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000230


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name